Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA) · developed by OnKure
OKI-219 is an orally bioavailable, mutant-selective inhibitor of the PIK3CA H1047R mutant form of the PI3K p110alpha catalytic subunit. It blocks PI3K/Akt/mTOR signaling in PIK3CA H1047R-mutant tumor cells, and it is studied in advanced cancer, breast cancer, and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06239467 | Phase 1 | Advanced Cancer | Active not recruiting | OKUR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced Solid TumorsBreast CancerPI3K Gene Mutation
See OKUR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OKUR catalysts and pipeline →